Meyer Jaimie P, Moghimi Yavar, Marcus Ruthanne, Lim Joseph K, Litwin Alain H, Altice Frederick L
Section of Infectious Diseases, AIDS Program, Yale School of Medicine, New Haven, CT, United States.
Department of Behavioral Health, Whitman-Walker Health, Washington, DC, United States.
Int J Drug Policy. 2015 Oct;26(10):922-35. doi: 10.1016/j.drugpo.2015.05.002. Epub 2015 May 17.
With the explosion of newly available direct acting antiviral (DAA) Hepatitis C virus (HCV) treatments that demonstrate 95% sustained virologic response (SVR) rates, evidence-based strategies are urgently needed to achieve real-world effectiveness in challenging patient populations. While HIV is incurable, lessons from over 30 years of experience overcoming obstacles to the HIV treatment cascade could be applied to the HCV context.
Using Institute of Medicine guidelines, we conducted a systematic review of published interventions from PubMed, Medline, GoogleScholar, EmBASE, and PsychInfo bibliographic databases and citation indices. Abstracts were first screened by three independent reviewers and studies were included if they involved original research, described a specific intervention, were published in English in a peer-reviewed journal between 2001 and 2014, and had full text available.
Evidence-based interventions to enhance HCV assessment, treatment, and adherence generally fell into one of 4 categories, including those involving: (1) diagnosis or case-finding; (2) linkage to HCV care; (3) pre-therapeutic evaluation or treatment initiation; or (4) treatment adherence. While most available eligible studies described interventions using non-contemporary interferon-based HCV treatments, future research will need to address how these interventions apply to the context of well-tolerated, simple, oral treatment regimens. In some cases, we explored how HIV-specific interventions might be modified to fit the HCV spectrum of care engagement.
Evidence-based interventions should be strategically incorporated into HCV treatment implementation efforts to most effectively deliver treatment and maximize treatment outcomes.
随着新型直接作用抗病毒(DAA)丙型肝炎病毒(HCV)治疗药物的大量涌现,这些药物显示出95%的持续病毒学应答(SVR)率,因此迫切需要基于证据的策略,以便在具有挑战性的患者群体中实现实际疗效。虽然HIV无法治愈,但30多年来克服HIV治疗流程障碍的经验教训可应用于HCV治疗。
我们依据医学研究所的指南,对来自PubMed、Medline、GoogleScholar、EmBASE和PsychInfo书目数据库及引文索引中已发表的干预措施进行了系统综述。摘要首先由三位独立评审员进行筛选,若研究涉及原创研究、描述了特定干预措施、于2001年至2014年间在同行评审期刊上以英文发表且有全文可供获取,则纳入研究。
增强HCV评估、治疗及依从性的基于证据的干预措施通常可分为4类,包括那些涉及:(1)诊断或病例发现;(2)与HCV治疗的衔接;(3)治疗前评估或治疗启动;或(4)治疗依从性。虽然大多数现有符合条件的研究描述了使用非当代基于干扰素的HCV治疗方法的干预措施,但未来研究需要探讨这些干预措施如何应用于耐受性良好、简单的口服治疗方案背景下。在某些情况下,我们探讨了如何修改针对HIV的干预措施以适应HCV治疗参与范围。
基于证据的干预措施应策略性地纳入HCV治疗实施工作中,以最有效地提供治疗并最大化治疗效果。